glp-1 receptor brain agonists show promise in treating substance use disorders Frontiers | GLP-1 Suppresses Feeding

mono agonists CT-388 has no post-marketing safety data (it is not yet approved)

They also review past treatment, including older diet drugs, which may carry different risks

Complete clinical data, dose analysis, side effects, and Canadian availability timeline

Healthcare providers may recommend starting with a lower dose and gradually increasing it based on observed effects and patient tolerance

therefore, it is more plausible that an effective vascular improvement is reached in mildmoderate vasculogenic ED patients, specifically mediated by l-ARG supplementation, as demonstrated by the evidence of PSV values compatible with absence of ED in a subset of mildmoderate vasculogenic ED patients at study completion

As with all medications, Saxenda can cause side effects